Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.